 |
 |

Is There Any Hope for Vitamin E?
B. Greg Brown, MD, PhD;
John Crowley, PhD
JAMA. 2005;293:1387-1390.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
During the past 15 years, epidemiological,1-2 basic biological,3-5 and experimental studies on atherosclerosis have supported the hypothesis that antioxidants protect against atherosclerosis6-8 by limiting low-density lipoprotein oxidation in the arterial wall. This mechanism inhibits the pathological accumulation of cholesteryl ester in plaque via the macrophage scavenger receptor, a process that can cause plaque rupture and cardiovascular events.9-10 Similarly, biological mechanisms have been identified in carcinogenesis that may be blocked by antioxidants.11-14 In the past decade, a number of prospective, randomized, placebo-controlled, 3- to 6-year clinical trials have been published, testing the effect of vitamin E and other antioxidant vitamins or their combinations on clinical manifestations of cardiovascular disease and cancer.15-21 These trials have surprisingly yet consistently shown that commonly used antioxidant vitamin regimens (vitamins E, C, beta carotene, or a combination) do not significantly reduce overall cardiovascular events or cancer.
Why not? . . . [Full Text of this Article]
Author Affiliations: Department of Medicine, Cardiology Division, University of Washington School of Medicine, Seattle (Dr Brown); Department of Cancer Research and Biostatistics, Fred Hutchinson Cancer Research Center; and Department of Biostatistics, University of Washington School of Public Health and Community Medicine, Seattle (Dr Crowley).
RELATED ARTICLE
Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial
The HOPE and HOPE-TOO Trial Investigators
JAMA. 2005;293(11):1338-1347.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Dual Therapy With Statins and Antioxidants Is Superior to Statins Alone in Decreasing the Risk of Cardiovascular Disease in a Subgroup of Middle-Aged Individuals With Both Diabetes Mellitus and the Haptoglobin 2-2 Genotype
Blum et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:e18-e20.
FULL TEXT
Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial
Milman et al.
Arterioscler. Thromb. Vasc. Bio. 2008;28:341-347.
ABSTRACT
| FULL TEXT
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic et al.
JAMA 2007;297:842-857.
ABSTRACT
| FULL TEXT
Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
Blum et al.
J Am Coll Cardiol 2007;49:82-87.
ABSTRACT
| FULL TEXT
Vitamin E Not Helpful Against Heart Disease and Cancer
JWatch Emergency Med. 2005;2005:4-4.
FULL TEXT
Mild Cognitive Impairment -- No Benefit from Vitamin E, Little from Donepezil
Blacker
NEJM 2005;352:2439-2441.
FULL TEXT
From the Library
Br. J. Ophthalmol. 2005;89:788-788.
FULL TEXT
It Looks HOPEless for Vitamin E
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT
|